First randomized Phase III trial confirming the efficacy of MET inhibition in patients with advanced NSCLC and acquired MET amplification after ...
Major differences between eGFR based on cystatin C compared with creatinine were associated with higher rates for all-cause mortality, CV events and kidney failure for outpatients, according to data ...
Chinese pharma Hansoh Pharma (HKEX: 3692) has secured approval from China’s National Medical Products Administration for an ...
The dual inhibition of PD-1 and VEGF pathways by ivonescimab aims to enhance immune response and limit tumor angiogenesis, ...
SurvivorNet on MSN
Targeted therapy in a shot: New approval for EGFR-mutated lung cancer can improve day-to-day life for patients
Rybrevant Faspro, the new subcutaneous version of amivantamab, was approved for patients with a specific form of lung cancer ...
Combining TRT with EGFR-TKIs significantly improves PFS and OS in EGFR-mutated oligo-organ metastatic NSCLC patients compared to EGFR-TKIs alone. The study suggests personalized treatment approaches, ...
The Alpestria-1 study enrolled (in France, USA and Spain) 26 patients with Alport syndrome at high risk of a rapid loss of kidney function despite stable multiple SoC drugs, including ...
This case describes a woman in her mid-40s with recurrent colorectal cancer who developed severe dermatologic toxicity during ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback